AbbVie (NYSE: ABBV) has long been a darling of dividend growth investors, and for good reason. Since its spinoff from Abbott ...

Pharmaceutical giant AbbVie has sued cancer treatment maker BeiGene in Chicago federal court, accusing it of stealing trade ...

The FDA has faulted AbbVie’s promotion of the migraine drug Ubrelvy, calling the company out for an ad featuring Serena ...

AbbVie’s migraine drug Ubrelvy (ubrogepant) is slated to be the top-selling drug in the migraine space in 2033 across the ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

The FDA has scolded AbbVie for making false and misleading claims about a TV ad about a migraine pill that features Serena ...

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...

The North Chicago pharma giant is accusing a former employee who joined a competitor of disclosing valuable development ...

UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its ...

AbbVie's longtime CEO, Richard Gonzalez, who held his position since the business spun off from Abbott Laboratories in 2013, ...

For years, the healthcare industry has been a cornerstone of the economy, offering resilience in both stable and uncertain ...

Just a few short weeks after winning an FDA Fast Track tag for its investigational BTK degrader in certain blood cancers, ...